Pazopanib Tops Temsirolimus in Intermediate-Risk Clear Cell RCCFebruary 13th 2018
Pazopanib was not associated with prolonged progression-free survival compared with temsirolimus among patients with advanced clear-cell renal cell carcinoma, but a subgroup analysis of intermediate-risk patients offered some reason for optimism.
Axitinib/Pembrolizumab Safe, Active in Untreated Kidney CancerFebruary 12th 2018
Combining axitinib and pembrolizumab is “safe and tolerable” among patients with previously untreated advanced renal cell carcinoma, with 73% of patients responding, according to findings from an open-label, phase Ib trial.
SM-88 Offers Promising Safety in Recurrent Localized Prostate CancerFebruary 12th 2018
Researchers reported promising safety data from an ongoing phase Ib/II clinical trial for SM-88, an investigational combination therapy that might one day offer an alternative to androgen deprivation therapy for men with recurrent, nonmetastatic prostate cancer.
Enzalutamide Delays Metastasis in Castration-Resistant Prostate CancerFebruary 9th 2018
Enzalutamide resulted in a 71% reduction in metastatic disease risk among men with castration-resistant prostate cancer and rapid prostate-specific antigen doubling time, according to the first interim analysis of data from the phase III PROSPER trial.
FDA Approves Abiraterone/Prednisone for Metastatic Prostate CancerFebruary 8th 2018
The US Food and Drug Administration has approved abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic prostate cancer patients with high-risk, castration-sensitive disease.
First-Line Atezolizumab/Bevacizumab Well-Tolerated in Metastatic RCCFebruary 5th 2018
Adding atezolizumab and bevacizumab to standard care was tolerable and slowed tumor growth in patients with previously untreated clear-cell or sarcomatoid-histology metastatic renal cell carcinoma when compared to sunitinib, according to findings from a phase III study.
Apalutamide Delays Metastasis in Prostate CancerFebruary 5th 2018
Apalutamide was well-tolerated and associated with delayed metastasis in men with high-risk castration-resistant prostate cancer that has become refractory to conventional hormone therapy, according to an early interim analysis of the phase III SPARTAN clinical trial.
Adjuvant vs Salvage Radiotherapy in High-Risk Prostate CancerFebruary 3rd 2018
Adjuvant radiotherapy after prostatectomy resulted in lower rates of biochemical recurrence, distant metastases, and death compared with surveillance followed by early-salvage radiotherapy in patients with high-risk prostate cancer, according to a new study.
FDA Approves Frontline Cabozantinib for Advanced RCCJanuary 3rd 2018
The FDA has expanded the label for cabozantinib (Cabometyx) to include first-line treatment of advanced renal cell carcinoma regardless of treatment status. Cabozantinib was initially approved in patients who had previously received anti-angiogenic therapy.
Educational Interventions Can Improve Bone Care in Prostate Cancer PatientsJanuary 2nd 2018
Educational strategies including pamphlets and recommendations from family physicians and support from a specialist can improve bone care in men with prostate cancer undergoing androgen deprivation therapy.
Pooled Analysis Shows Avelumab Promising in Advanced Urothelial CarcinomaDecember 16th 2017
The immune checkpoint inhibitor avelumab showed promising antitumor activity and a manageable toxicity profile in patients with platinum-refractory metastatic urothelial carcinoma, according to a new analysis.
Clinical Decision Making in Surveillance of Non–Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular MarkersDecember 15th 2017
In this article, we discuss the requirements for development and validation of urine markers and the factors that hamper their clinical implementation. We also review current surveillance guidelines for NMIBC and provide an overview of approved urine markers for the detection and surveillance of NMIBC.
Combo Antiemetic Therapy Safe, Effective for Testicular Cancer Patients on Cisplatin ChemotherapyDecember 12th 2017
Researchers found that combining palonosetron, aprepitant, and dexamethasone represents an effective and well-tolerated treatment to prevent CINV in testicular cancer patients receiving cisplatin.